{"entity":{"id":"jw-therapeutics","kind":"company","name":"JW Therapeutics","aka":["药明巨诺","JW (Cayman) Therapeutics"],"tldr":"JW Therapeutics, a Juno and WuXi AppTec joint venture, made relma-cel, the first CAR-T developed and manufactured in China to be approved.","summary":"Relmacabtagene autoleucel (Carteyva) approved 2021 for large B-cell lymphoma and 2022 for follicular lymphoma; pipeline in mantle cell lymphoma, leukaemia and autoimmune disease. Its commercial struggle (list price around CN¥ 1.29 million, not NRDL-listed, provincial supplementary insurance filling some of the gap) is the case study for how China pays for cell therapy.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.jwtherapeutics.com/en/"}],"tags":["china"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["car-t"],"targets":[],"drugs":["relmacabtagene-autoleucel"],"companies":["wuxi-apptec","bms"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06093841","nct06479356","nct04718883"],"people":[],"bottlenecks":["b-drug-pricing","b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"cell-therapy","website":"https://www.jwtherapeutics.com/en/","ticker":"2126.HK","founded":2016,"investors":[],"funding":[]},"route":"/companies/jw-therapeutics/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"drug":[{"id":"relmacabtagene-autoleucel","kind":"drug","name":"Relmacabtagene autoleucel","route":"/drugs/relmacabtagene-autoleucel/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"wuxi-apptec","kind":"company","name":"WuXi AppTec","route":"/companies/wuxi-apptec/"}],"trial":[{"id":"nct04718883","kind":"trial","name":"CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma","route":"/trials/nct04718883/"},{"id":"nct06479356","kind":"trial","name":"CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma","route":"/trials/nct06479356/"},{"id":"reliance","kind":"trial","name":"RELIANCE","route":"/trials/reliance/"},{"id":"nct06093841","kind":"trial","name":"Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL","route":"/trials/nct06093841/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"person":[{"id":"li-ge","kind":"person","name":"Ge Li","route":"/people/li-ge/"}]}}